{
    "abstract": "Background: A high-dose, split-virion inactivated trivalent influenza vaccine (IIV3-HD; Fluzone\u00ae High-Dose, Sanofi Pasteur) is available for adults \u226565 years of age. This study examined the safety and immunogenicity of a quadrivalent high-dose split-virion inactivated influenza vaccine (IIV4-HD). Methods: This was a randomized, modified double-blind, active-controlled, multi-center trial in healthy adults \u226565 years of age. Subjects were randomized in a 4:1:1 ratio to receive a single intramuscular injection of IIV4-HD, the licensed IIV3-HD, or an IIV3-HD containing the alternate B-lineage strain. Hemagglutination inhibition (HAI), seroneutralisation, and anti-neuraminidase antibody titers were measured at baseline and day 28. Solicited reactions were collected for up to 7 days, unsolicited adverse events up to 28 days, and serious adverse events up to 180 days. The primary immunogenicity objective was to demonstrate that IIV4-HD induces HAI geometric mean titers (GMTs) and seroconversion rates that are non-inferior to those induced by IIV3-HD. Secondary objectives were to describe the safety of IIV4-HD and IIV3-HD and to demonstrate that IIV4-HD induces HAI GMTs and seroconversion rates that are superior to those induced by IIV3-HD not containing the same B-lineage strain. Results: The study included 2670 adults \u226565 years of age. For all four strains, HAI GMTs and seroconversion rates induced by IIV4-HD were non-inferior to those induced by IIV3-HDs containing the same strains. For both B strains, HAI GMTs and seroconversion rates induced by IIV4-HD were superior to those induced by IIV3-HD not containing the same B\u2013lineage strain. Seroneutralisation and anti-neuraminidase antibody responses, measured in a subset of subjects, were similar. No new safety concerns were identified, and the safety profiles of IIV4-HD and IIV3-HD were similar. Conclusions: Adding a second B strain in IIV4-HD resulted in improved immunogenicity against the added strain without compromising the immunogenicity of the other strains or the vaccine's tolerability. Clinical trial registration: NCT03282240.",
    "author_highlights": [
        {
            "endOffset": 20303,
            "sentence": "High-dose trivalent influenza vaccine is licensed for adults \u226565 years of age.",
            "startOffset": 20225
        },
        {
            "endOffset": 20384,
            "sentence": "A quadrivalent formulation with antigen from both B lineages has been developed.",
            "startOffset": 20304
        },
        {
            "endOffset": 20461,
            "sentence": "Adding the second B strain improved immunogenicity against the added strain.",
            "startOffset": 20385
        },
        {
            "endOffset": 20521,
            "sentence": "Immunogenicity against the other strains remained the same.",
            "startOffset": 20462
        },
        {
            "endOffset": 20594,
            "sentence": "The vaccine\u2019s tolerability was unaffected by adding the second B strain.",
            "startOffset": 20522
        }
    ],
    "bib_entries": {
        "b0005": null,
        "b0010": {
            "authors": [
                {
                    "first": "Jessica C.",
                    "initial": "J.C.",
                    "last": "Seidman"
                },
                {
                    "first": "Stephanie A.",
                    "initial": "S.A.",
                    "last": "Richard"
                },
                {
                    "first": "C\u00e9cile",
                    "initial": "C.",
                    "last": "Viboud"
                },
                {
                    "first": "Mark A.",
                    "initial": "M.A.",
                    "last": "Miller"
                }
            ],
            "doi": "10.1111/j.1750-2659.2011.00268.x",
            "firstpage": "52",
            "issn": "17502640",
            "lastpage": "62",
            "pmid": "21668661",
            "pub_year": 2012,
            "title": "Quantitative review of antibody response to inactivated seasonal influenza vaccines",
            "volume": "6"
        },
        "b0015": {
            "authors": [
                {
                    "first": "Jan",
                    "initial": "J.",
                    "last": "Smetana"
                },
                {
                    "first": "Roman",
                    "initial": "R.",
                    "last": "Chlibek"
                },
                {
                    "first": "Jana",
                    "initial": "J.",
                    "last": "Shaw"
                },
                {
                    "first": "Miroslav",
                    "initial": "M.",
                    "last": "Splino"
                },
                {
                    "first": "Roman",
                    "initial": "R.",
                    "last": "Prymula"
                }
            ],
            "doi": "10.1080/21645515.2017.1343226",
            "firstpage": "540",
            "issn": "21645515",
            "lastpage": "549",
            "pmid": "28708957",
            "pub_year": 2018,
            "title": "Influenza vaccination in the elderly",
            "volume": "14"
        },
        "b0020": {
            "authors": [
                {
                    "first": "Robert B.",
                    "initial": "R.B.",
                    "last": "Couch"
                },
                {
                    "first": "Wendy A.",
                    "initial": "W.A.",
                    "last": "Keitel"
                },
                {
                    "first": "Thomas R.",
                    "initial": "T.R.",
                    "last": "Cate"
                }
            ],
            "firstpage": "S38",
            "issn": "00221899",
            "lastpage": "S44",
            "pmid": "9240693",
            "pub_year": 1997,
            "title": "Improvement of inactivated influenza virus vaccines",
            "volume": "176"
        },
        "b0025": {
            "authors": [
                {
                    "first": "Kamran",
                    "initial": "K.",
                    "last": "Haq"
                },
                {
                    "first": "Janet E.",
                    "initial": "J.E.",
                    "last": "McElhaney"
                }
            ],
            "doi": "10.1016/j.coi.2014.03.008",
            "firstpage": "38",
            "issn": "09527915",
            "lastpage": "42",
            "pmid": "24769424",
            "pub_year": 2014,
            "title": "Immunosenescence: Influenza vaccination and the elderly",
            "volume": "29"
        },
        "b0030": {
            "authors": [
                {
                    "first": "Corwin A.",
                    "initial": "C.A.",
                    "last": "Robertson"
                },
                {
                    "first": "Carlos A.",
                    "initial": "C.A.",
                    "last": "DiazGranados"
                },
                {
                    "first": "Michael D.",
                    "initial": "M.D.",
                    "last": "Decker"
                },
                {
                    "first": "Ayman",
                    "initial": "A.",
                    "last": "Chit"
                },
                {
                    "first": "Monica",
                    "initial": "M.",
                    "last": "Mercer"
                },
                {
                    "first": "David P.",
                    "initial": "D.P.",
                    "last": "Greenberg"
                }
            ],
            "doi": "10.1080/14760584.2016.1254044",
            "firstpage": "1495",
            "issn": "14760584",
            "lastpage": "1505",
            "pmid": "27813430",
            "pub_year": 2016,
            "title": "Fluzone\u00ae High-Dose Influenza Vaccine",
            "volume": "15"
        },
        "b0035": {
            "authors": [
                {
                    "first": "Carlos A.",
                    "initial": "C.A.",
                    "last": "DiazGranados"
                },
                {
                    "first": "Andrew J.",
                    "initial": "A.J.",
                    "last": "Dunning"
                },
                {
                    "first": "Murray",
                    "initial": "M.",
                    "last": "Kimmel"
                },
                {
                    "first": "Daniel",
                    "initial": "D.",
                    "last": "Kirby"
                },
                {
                    "first": "John",
                    "initial": "J.",
                    "last": "Treanor"
                },
                {
                    "first": "Avi",
                    "initial": "A.",
                    "last": "Collins"
                },
                {
                    "first": "Richard",
                    "initial": "R.",
                    "last": "Pollak"
                },
                {
                    "first": "Janet",
                    "initial": "J.",
                    "last": "Christoff"
                },
                {
                    "first": "John",
                    "initial": "J.",
                    "last": "Earl"
                },
                {
                    "first": "Victoria",
                    "initial": "V.",
                    "last": "Landolfi"
                },
                {
                    "first": "Earl",
                    "initial": "E.",
                    "last": "Martin"
                },
                {
                    "first": "Sanjay",
                    "initial": "S.",
                    "last": "Gurunathan"
                },
                {
                    "first": "Richard",
                    "initial": "R.",
                    "last": "Nathan"
                },
                {
                    "first": "David P.",
                    "initial": "D.P.",
                    "last": "Greenberg"
                },
                {
                    "first": "Nadia G.",
                    "initial": "N.G.",
                    "last": "Tornieporth"
                },
                {
                    "first": "Michael D.",
                    "initial": "M.D.",
                    "last": "Decker"
                },
                {
                    "first": "H. Keipp",
                    "initial": "H.K.",
                    "last": "Talbot"
                }
            ],
            "doi": "10.1056/NEJMoa1315727",
            "firstpage": "635",
            "issn": "00284793",
            "lastpage": "645",
            "pmid": "25119609",
            "pub_year": 2014,
            "title": "Efficacy of high-dose versus standard-dose influenza vaccine in older adults",
            "volume": "371"
        },
        "b0040": {
            "authors": [
                {
                    "first": "Debbie L.",
                    "initial": "D.L.",
                    "last": "Becker"
                },
                {
                    "first": "Ayman",
                    "initial": "A.",
                    "last": "Chit"
                },
                {
                    "first": "Carlos A.",
                    "initial": "C.A.",
                    "last": "DiazGranados"
                },
                {
                    "first": "Michael",
                    "initial": "M.",
                    "last": "Maschio"
                },
                {
                    "first": "Eddy",
                    "initial": "E.",
                    "last": "Yau"
                },
                {
                    "first": "Michael",
                    "initial": "M.",
                    "last": "Drummond"
                }
            ],
            "doi": "10.1080/21645515.2016.1215395",
            "firstpage": "3036",
            "issn": "21645515",
            "lastpage": "3042",
            "pmid": "27669017",
            "pub_year": 2016,
            "title": "High-dose inactivated influenza vaccine is associated with cost savings and better outcomes compared to standard-dose inactivated influenza vaccine in Canadian seniors",
            "volume": "12"
        },
        "b0045": {
            "authors": [
                {
                    "first": "Stefan",
                    "initial": "S.",
                    "last": "Gravenstein"
                },
                {
                    "first": "H. Edward",
                    "initial": "H.E.",
                    "last": "Davidson"
                },
                {
                    "first": "Monica",
                    "initial": "M.",
                    "last": "Taljaard"
                },
                {
                    "first": "Jessica",
                    "initial": "J.",
                    "last": "Ogarek"
                },
                {
                    "first": "Pedro",
                    "initial": "P.",
                    "last": "Gozalo"
                },
                {
                    "first": "Lisa",
                    "initial": "L.",
                    "last": "Han"
                },
                {
                    "first": "Vincent",
                    "initial": "V.",
                    "last": "Mor"
                }
            ],
            "doi": "10.1016/S2213-2600(17)30235-7",
            "firstpage": "738",
            "issn": "22132600",
            "lastpage": "746",
            "pmid": "28736045",
            "pub_year": 2017,
            "title": "Comparative effectiveness of high-dose versus standard-dose influenza vaccination on numbers of US nursing home residents admitted to hospital: a cluster-randomised trial",
            "volume": "5"
        },
        "b0050": {
            "authors": [
                {
                    "first": "Carlos A.",
                    "initial": "C.A.",
                    "last": "DiazGranados"
                },
                {
                    "first": "Corwin A.",
                    "initial": "C.A.",
                    "last": "Robertson"
                },
                {
                    "first": "H. Keipp",
                    "initial": "H.K.",
                    "last": "Talbot"
                },
                {
                    "first": "Victoria",
                    "initial": "V.",
                    "last": "Landolfi"
                },
                {
                    "first": "Andrew J.",
                    "initial": "A.J.",
                    "last": "Dunning"
                },
                {
                    "first": "David P.",
                    "initial": "D.P.",
                    "last": "Greenberg"
                }
            ],
            "doi": "10.1016/j.vaccine.2015.07.006",
            "firstpage": "4988",
            "issn": "0264410X",
            "lastpage": "4993",
            "pmid": "26212007",
            "pub_year": 2015,
            "title": "Prevention of serious events in adults 65 years of age or older: A comparison between high-dose and standard-dose inactivated influenza vaccines",
            "volume": "33"
        },
        "b0055": {
            "authors": [
                {
                    "first": "Hector S.",
                    "initial": "H.S.",
                    "last": "Izurieta"
                },
                {
                    "first": "Yoganand",
                    "initial": "Y.",
                    "last": "Chillarige"
                },
                {
                    "first": "Jeffrey",
                    "initial": "J.",
                    "last": "Kelman"
                },
                {
                    "first": "Yuqin",
                    "initial": "Y.",
                    "last": "Wei"
                },
                {
                    "first": "Yun",
                    "initial": "Y.",
                    "last": "Lu"
                },
                {
                    "first": "Wenjie",
                    "initial": "W.",
                    "last": "Xu"
                },
                {
                    "first": "Michael",
                    "initial": "M.",
                    "last": "Lu"
                },
                {
                    "first": "Douglas",
                    "initial": "D.",
                    "last": "Pratt"
                },
                {
                    "first": "Steve",
                    "initial": "S.",
                    "last": "Chu"
                },
                {
                    "first": "Michael",
                    "initial": "M.",
                    "last": "Wernecke"
                },
                {
                    "first": "Thomas",
                    "initial": "T.",
                    "last": "Macurdy"
                },
                {
                    "first": "Richard",
                    "initial": "R.",
                    "last": "Forshee"
                }
            ],
            "doi": "10.1093/infdis/jiy716",
            "firstpage": "1255",
            "issn": "00221899",
            "lastpage": "1264",
            "pmid": "30561688",
            "pub_year": 2019,
            "title": "Relative Effectiveness of Cell-Cultured and Egg-Based Influenza Vaccines among Elderly Persons in the United States, 2017-2018",
            "volume": "220"
        },
        "b0060": {
            "authors": [
                {
                    "first": "Steve G.",
                    "initial": "S.G.",
                    "last": "Robison"
                },
                {
                    "first": "Ann R.",
                    "initial": "A.R.",
                    "last": "Thomas"
                }
            ],
            "doi": "10.1016/j.vaccine.2018.09.050",
            "firstpage": "6683",
            "issn": "0264410X",
            "lastpage": "6687",
            "pmid": "30287157",
            "pub_year": 2018,
            "title": "Assessing the effectiveness of high-dose influenza vaccine in preventing hospitalization among seniors, and observations on the limitations of effectiveness study design",
            "volume": "36"
        },
        "b0065": {
            "authors": [
                {
                    "first": "David K.",
                    "initial": "D.K.",
                    "last": "Shay"
                },
                {
                    "first": "Yoganand",
                    "initial": "Y.",
                    "last": "Chillarige"
                },
                {
                    "first": "Jeffrey",
                    "initial": "J.",
                    "last": "Kelman"
                },
                {
                    "first": "Richard A.",
                    "initial": "R.A.",
                    "last": "Forshee"
                },
                {
                    "first": "Ivo M.",
                    "initial": "I.M.",
                    "last": "Foppa"
                },
                {
                    "first": "Michael",
                    "initial": "M.",
                    "last": "Wernecke"
                },
                {
                    "first": "Yun",
                    "initial": "Y.",
                    "last": "Lu"
                },
                {
                    "first": "Jill M.",
                    "initial": "J.M.",
                    "last": "Ferdinands"
                },
                {
                    "first": "Arjun",
                    "initial": "A.",
                    "last": "Iyengar"
                },
                {
                    "first": "Alicia M.",
                    "initial": "A.M.",
                    "last": "Fry"
                },
                {
                    "first": "Chris",
                    "initial": "C.",
                    "last": "Worrall"
                },
                {
                    "first": "Hector S.",
                    "initial": "H.S.",
                    "last": "Izurieta"
                }
            ],
            "doi": "10.1093/infdis/jiw641",
            "firstpage": "510",
            "issn": "00221899",
            "lastpage": "517",
            "pmid": "28329311",
            "pub_year": 2017,
            "title": "Comparative effectiveness of high-dose versus standard-dose influenza vaccines among US medicare beneficiaries in preventing postinfluenza deaths during 2012-2013 and 2013-2014",
            "volume": "215"
        },
        "b0070": {
            "authors": [
                {
                    "first": "Yinong",
                    "initial": "Y.",
                    "last": "Young-Xu"
                },
                {
                    "first": "Julia Thornton",
                    "initial": "J.T.",
                    "last": "Snider"
                },
                {
                    "first": "Robertus",
                    "initial": "R.",
                    "last": "van Aalst"
                },
                {
                    "first": "Salaheddin M.",
                    "initial": "S.M.",
                    "last": "Mahmud"
                },
                {
                    "first": "Edward W.",
                    "initial": "E.W.",
                    "last": "Thommes"
                },
                {
                    "first": "Jason K.H.",
                    "initial": "J.K.H.",
                    "last": "Lee"
                },
                {
                    "first": "David P.",
                    "initial": "D.P.",
                    "last": "Greenberg"
                },
                {
                    "first": "Ayman",
                    "initial": "A.",
                    "last": "Chit"
                }
            ],
            "doi": "10.1016/j.vaccine.2019.01.063",
            "firstpage": "1484",
            "issn": "0264410X",
            "lastpage": "1490",
            "pmid": "30745146",
            "pub_year": 2019,
            "title": "Analysis of relative effectiveness of high-dose versus standard-dose influenza vaccines using an instrumental variable method",
            "volume": "37"
        },
        "b0075": {
            "authors": [
                {
                    "first": "Yinong",
                    "initial": "Y.",
                    "last": "Young-Xu"
                },
                {
                    "first": "Robertus",
                    "initial": "R.",
                    "last": "Van Aalst"
                },
                {
                    "first": "Salaheddin M.",
                    "initial": "S.M.",
                    "last": "Mahmud"
                },
                {
                    "first": "Kenneth J.",
                    "initial": "K.J.",
                    "last": "Rothman"
                },
                {
                    "first": "Julia Thornton",
                    "initial": "J.T.",
                    "last": "Snider"
                },
                {
                    "first": "Daniel",
                    "initial": "D.",
                    "last": "Westreich"
                },
                {
                    "first": "Vincent",
                    "initial": "V.",
                    "last": "Mor"
                },
                {
                    "first": "Stefan",
                    "initial": "S.",
                    "last": "Gravenstein"
                },
                {
                    "first": "Jason K.H.",
                    "initial": "J.K.H.",
                    "last": "Lee"
                },
                {
                    "first": "Edward W.",
                    "initial": "E.W.",
                    "last": "Thommes"
                },
                {
                    "first": "Michael D.",
                    "initial": "M.D.",
                    "last": "Decker"
                },
                {
                    "first": "Ayman",
                    "initial": "A.",
                    "last": "Chit"
                }
            ],
            "doi": "10.1093/infdis/jiy088",
            "firstpage": "1718",
            "issn": "00221899",
            "lastpage": "1727",
            "pmid": "29452380",
            "pub_year": 2018,
            "title": "Relative vaccine effectiveness of high-dose versus standard-dose influenza vaccines among veterans health administration patients",
            "volume": "217"
        },
        "b0080": {
            "authors": [
                {
                    "first": "Krista",
                    "initial": "K.",
                    "last": "Wilkinson"
                },
                {
                    "first": "Yichun",
                    "initial": "Y.",
                    "last": "Wei"
                },
                {
                    "first": "Andrea",
                    "initial": "A.",
                    "last": "Szwajcer"
                },
                {
                    "first": "Rasheda",
                    "initial": "R.",
                    "last": "Rabbani"
                },
                {
                    "first": "Ryan",
                    "initial": "R.",
                    "last": "Zarychanski"
                },
                {
                    "first": "Ahmed M.",
                    "initial": "A.M.",
                    "last": "Abou-Setta"
                },
                {
                    "first": "Salaheddin M.",
                    "initial": "S.M.",
                    "last": "Mahmud"
                }
            ],
            "doi": "10.1016/j.vaccine.2017.03.092",
            "firstpage": "2775",
            "issn": "0264410X",
            "lastpage": "2780",
            "pmid": "28431815",
            "pub_year": 2017,
            "title": "Efficacy and safety of high-dose influenza vaccine in elderly adults: A systematic review and meta-analysis",
            "volume": "35"
        },
        "b0085": {
            "authors": [
                {
                    "first": "Sandrine I.",
                    "initial": "S.I.",
                    "last": "Samson"
                },
                {
                    "first": "Phillip S.",
                    "initial": "P.S.",
                    "last": "Leventhal"
                },
                {
                    "first": "Camille",
                    "initial": "C.",
                    "last": "Salamand"
                },
                {
                    "first": "Ya",
                    "initial": "Y.",
                    "last": "Meng"
                },
                {
                    "first": "Bruce T.",
                    "initial": "B.T.",
                    "last": "Seet"
                },
                {
                    "first": "Victoria",
                    "initial": "V.",
                    "last": "Landolfi"
                },
                {
                    "first": "David",
                    "initial": "D.",
                    "last": "Greenberg"
                },
                {
                    "first": "Rosalind",
                    "initial": "R.",
                    "last": "Hollingsworth"
                }
            ],
            "doi": "10.1080/14760584.2019.1575734",
            "firstpage": "295",
            "issn": "14760584",
            "lastpage": "308",
            "pmid": "30689467",
            "pub_year": 2019,
            "title": "Immunogenicity of high-dose trivalent inactivated influenza vaccine: a systematic review and meta-analysis",
            "volume": "18"
        },
        "b0090": {
            "authors": [
                {
                    "first": "Saverio",
                    "initial": "S.",
                    "last": "Caini"
                },
                {
                    "first": "Q. Sue",
                    "initial": "Q.S.",
                    "last": "Huang"
                },
                {
                    "first": "Meral A.",
                    "initial": "M.A.",
                    "last": "Ciblak"
                },
                {
                    "first": "Gabriela",
                    "initial": "G.",
                    "last": "Kusznierz"
                },
                {
                    "first": "Rhonda",
                    "initial": "R.",
                    "last": "Owen"
                },
                {
                    "first": "Sonam",
                    "initial": "S.",
                    "last": "Wangchuk"
                },
                {
                    "first": "Cl\u00e1udio M.P.",
                    "initial": "C.M.P.",
                    "last": "Henriques"
                },
                {
                    "first": "Richard",
                    "initial": "R.",
                    "last": "Njouom"
                },
                {
                    "first": "Rodrigo A.",
                    "initial": "R.A.",
                    "last": "Fasce"
                },
                {
                    "first": "Hongjie",
                    "initial": "H.",
                    "last": "Yu"
                },
                {
                    "first": "Luzhao",
                    "initial": "L.",
                    "last": "Feng"
                },
                {
                    "first": "Maria",
                    "initial": "M.",
                    "last": "Zambon"
                },
                {
                    "first": "Alexey W.",
                    "initial": "A.W.",
                    "last": "Clara"
                },
                {
                    "first": "Herman",
                    "initial": "H.",
                    "last": "Kosasih"
                },
                {
                    "first": "Simona",
                    "initial": "S.",
                    "last": "Puzelli"
                },
                {
                    "first": "Herve A.",
                    "initial": "H.A.",
                    "last": "Kadjo"
                },
                {
                    "first": "Gideon",
                    "initial": "G.",
                    "last": "Emukule"
                },
                {
                    "first": "Jean Michel",
                    "initial": "J.M.",
                    "last": "Heraud"
                },
                {
                    "first": "Li Wei",
                    "initial": "L.W.",
                    "last": "Ang"
                },
                {
                    "first": "Marietjie",
                    "initial": "M.",
                    "last": "Venter"
                },
                {
                    "first": "Alla",
                    "initial": "A.",
                    "last": "Mironenko"
                },
                {
                    "first": "Lynnette",
                    "initial": "L.",
                    "last": "Brammer"
                },
                {
                    "first": "Le Thi Quynh",
                    "initial": "L.T.Q.",
                    "last": "Mai"
                },
                {
                    "first": "Fran\u00e7ois",
                    "initial": "F.",
                    "last": "Schellevis"
                },
                {
                    "first": "Stanley",
                    "initial": "S.",
                    "last": "Plotkin"
                },
                {
                    "first": "John",
                    "initial": "J.",
                    "last": "Paget"
                },
                {
                    "first": "Juan Manuel",
                    "initial": "J.M.",
                    "last": "Rudi"
                },
                {
                    "first": "Kunzang",
                    "initial": "K.",
                    "last": "Dorji"
                },
                {
                    "first": "Jo\u015be Ricardo Pio",
                    "initial": "J.R.P.",
                    "last": "Marins"
                },
                {
                    "first": "Walquiria Aparecida Ferreira",
                    "initial": "W.A.F.",
                    "last": "de Almeida"
                },
                {
                    "first": "Marie Astrid",
                    "initial": "M.A.",
                    "last": "Vernet"
                },
                {
                    "first": "Guy",
                    "initial": "G.",
                    "last": "Vernet"
                },
                {
                    "first": "Joseph",
                    "initial": "J.",
                    "last": "Bresee"
                },
                {
                    "first": "Winston",
                    "initial": "W.",
                    "last": "Andrade"
                },
                {
                    "first": "Juan",
                    "initial": "J.",
                    "last": "Yang"
                },
                {
                    "first": "Ming",
                    "initial": "M.",
                    "last": "Li"
                },
                {
                    "first": "Jenny",
                    "initial": "J.",
                    "last": "Lara"
                },
                {
                    "first": "Celina",
                    "initial": "C.",
                    "last": "de Lozano"
                },
                {
                    "first": "Richard",
                    "initial": "R.",
                    "last": "Pebody"
                },
                {
                    "first": "Joanna",
                    "initial": "J.",
                    "last": "Ellis"
                },
                {
                    "first": "Helen",
                    "initial": "H.",
                    "last": "Green"
                },
                {
                    "first": "Leticia",
                    "initial": "L.",
                    "last": "Castillo"
                },
                {
                    "first": "Maria Luisa",
                    "initial": "M.L.",
                    "last": "Matute"
                },
                {
                    "first": null,
                    "initial": null,
                    "last": "Nurhayati"
                },
                {
                    "first": "Isabella",
                    "initial": "I.",
                    "last": "Donatelli"
                },
                {
                    "first": "Coulibaly",
                    "initial": "C.",
                    "last": "Daouda"
                },
                {
                    "first": "Joshua A.",
                    "initial": "J.A.",
                    "last": "Mott"
                },
                {
                    "first": "Norosoa Harline",
                    "initial": "N.H.",
                    "last": "Razanajatovo"
                },
                {
                    "first": "Laurence",
                    "initial": "L.",
                    "last": "Randrianasolo"
                },
                {
                    "first": "Liza",
                    "initial": "L.",
                    "last": "Lopez"
                },
                {
                    "first": "Angel",
                    "initial": "A.",
                    "last": "Balmaseda"
                },
                {
                    "first": "Brechla",
                    "initial": "B.",
                    "last": "Moreno"
                },
                {
                    "first": "Jeffrey",
                    "initial": "J.",
                    "last": "Cutter"
                },
                {
                    "first": "Vernon J.",
                    "initial": "V.J.",
                    "last": "Lee"
                },
                {
                    "first": "Cheryl",
                    "initial": "C.",
                    "last": "Cohen"
                },
                {
                    "first": "Selim",
                    "initial": "S.",
                    "last": "Badur"
                },
                {
                    "first": null,
                    "initial": null,
                    "last": null
                }
            ],
            "doi": "10.1111/irv.12319",
            "firstpage": "3",
            "issn": "17502640",
            "lastpage": "12",
            "pmid": "26256290",
            "pub_year": 2015,
            "title": "Epidemiological and virological characteristics of influenza B: Results of the Global Influenza B Study",
            "volume": "9"
        },
        "b0095": {
            "authors": [
                {
                    "first": "V.",
                    "initial": "V.",
                    "last": "Tisa"
                },
                {
                    "first": "I.",
                    "initial": "I.",
                    "last": "Barberis"
                },
                {
                    "first": "V.",
                    "initial": "V.",
                    "last": "Faccio"
                },
                {
                    "first": "C.",
                    "initial": "C.",
                    "last": "Paganino"
                },
                {
                    "first": "C.",
                    "initial": "C.",
                    "last": "Trucchi"
                },
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Martini"
                },
                {
                    "first": "F.",
                    "initial": "F.",
                    "last": "Ansaldi"
                }
            ],
            "firstpage": "E28",
            "issn": "11212233",
            "lastpage": "E33",
            "pub_year": 2016,
            "title": "Quadrivalent influenza vaccine: A new opportunity to reduce the influenza burden",
            "volume": "57"
        },
        "b0100": {
            "authors": [
                {
                    "first": "David P.",
                    "initial": "D.P.",
                    "last": "Greenberg"
                },
                {
                    "first": "Corwin A.",
                    "initial": "C.A.",
                    "last": "Robertson"
                },
                {
                    "first": "Michael J.",
                    "initial": "M.J.",
                    "last": "Noss"
                },
                {
                    "first": "Mark M.",
                    "initial": "M.M.",
                    "last": "Blatter"
                },
                {
                    "first": "Rex",
                    "initial": "R.",
                    "last": "Biedenbender"
                },
                {
                    "first": "Michael D.",
                    "initial": "M.D.",
                    "last": "Decker"
                }
            ],
            "doi": "10.1016/j.vaccine.2012.11.074",
            "firstpage": "770",
            "issn": "0264410X",
            "lastpage": "776",
            "pmid": "23228813",
            "pub_year": 2013,
            "title": "Safety and immunogenicity of a quadrivalent inactivated influenza vaccine compared to licensed trivalent inactivated influenza vaccines in adults",
            "volume": "31"
        },
        "b0105": {
            "authors": [
                {
                    "first": "Laura",
                    "initial": "L.",
                    "last": "Couzens"
                },
                {
                    "first": "Jin",
                    "initial": "J.",
                    "last": "Gao"
                },
                {
                    "first": "Kim",
                    "initial": "K.",
                    "last": "Westgeest"
                },
                {
                    "first": "Matthew",
                    "initial": "M.",
                    "last": "Sandbulte"
                },
                {
                    "first": "Vladimir",
                    "initial": "V.",
                    "last": "Lugovtsev"
                },
                {
                    "first": "Ron",
                    "initial": "R.",
                    "last": "Fouchier"
                },
                {
                    "first": "Maryna",
                    "initial": "M.",
                    "last": "Eichelberger"
                }
            ],
            "doi": "10.1016/j.jviromet.2014.09.003",
            "firstpage": "7",
            "issn": "01660934",
            "lastpage": "14",
            "pmid": "25233882",
            "pub_year": 2014,
            "title": "An optimized enzyme-linked lectin assay to measure influenza A virus neuraminidase inhibition antibody titers in human sera",
            "volume": "210"
        },
        "b0110": {
            "authors": [
                {
                    "first": "Claude R.",
                    "initial": "C.R.",
                    "last": "Lambr\u00e9"
                },
                {
                    "first": "H\u00e9l\u00e8ne",
                    "initial": "H.",
                    "last": "Terzidis"
                },
                {
                    "first": "Anne",
                    "initial": "A.",
                    "last": "Greffard"
                },
                {
                    "first": "Robert G.",
                    "initial": "R.G.",
                    "last": "Webster"
                }
            ],
            "doi": "10.1016/0022-1759(90)90255-T",
            "firstpage": "49",
            "issn": "00221759",
            "lastpage": "57",
            "pmid": "1703190",
            "pub_year": 1990,
            "title": "Measurement of anti-influenza neuraminidase antibody using a peroxidase-linked lectin and microtitre plates coated with natural substrates",
            "volume": "135"
        },
        "b0115": null,
        "b0120": null,
        "b0125": {
            "authors": [
                {
                    "first": "Robert G.",
                    "initial": "R.G.",
                    "last": "Newcombe"
                }
            ],
            "doi": "10.1002/(SICI)1097-0258(19980430)17:8<873::AID-SIM779>3.0.CO;2-I",
            "firstpage": "873",
            "issn": "02776715",
            "lastpage": "890",
            "pmid": "9595617",
            "pub_year": 1998,
            "title": "Interval estimation for the difference between independent proportions: Comparison of eleven methods",
            "volume": "17"
        },
        "b0130": {
            "authors": [
                {
                    "first": "Jason K.H.",
                    "initial": "J.K.H.",
                    "last": "Lee"
                },
                {
                    "first": "Gary K.L.",
                    "initial": "G.K.L.",
                    "last": "Lam"
                },
                {
                    "first": "Thomas",
                    "initial": "T.",
                    "last": "Shin"
                },
                {
                    "first": "Jiyeon",
                    "initial": "J.",
                    "last": "Kim"
                },
                {
                    "first": "Anish",
                    "initial": "A.",
                    "last": "Krishnan"
                },
                {
                    "first": "David P.",
                    "initial": "D.P.",
                    "last": "Greenberg"
                },
                {
                    "first": "Ayman",
                    "initial": "A.",
                    "last": "Chit"
                }
            ],
            "doi": "10.1080/14760584.2018.1471989",
            "firstpage": "435",
            "issn": "14760584",
            "lastpage": "443",
            "pmid": "29715054",
            "pub_year": 2018,
            "title": "Efficacy and effectiveness of high-dose versus standard-dose influenza vaccination for older adults: a systematic review and meta-analysis",
            "volume": "17"
        },
        "b0135": {
            "authors": [
                {
                    "first": "David P.",
                    "initial": "D.P.",
                    "last": "Greenberg"
                },
                {
                    "first": "Corwin A.",
                    "initial": "C.A.",
                    "last": "Robertson"
                },
                {
                    "first": "H. Keipp",
                    "initial": "H.K.",
                    "last": "Talbot"
                },
                {
                    "first": "Michael D.",
                    "initial": "M.D.",
                    "last": "Decker"
                }
            ],
            "doi": "10.1080/21645515.2017.1344375",
            "firstpage": "2058",
            "issn": "21645515",
            "lastpage": "2064",
            "pmid": "28700265",
            "pub_year": 2017,
            "title": "Safety and immunogenicity of a quadrivalent influenza vaccine in adults 65\u00a0y of age and older",
            "volume": "13"
        },
        "b0140": {
            "authors": [
                {
                    "first": "Josefina B.",
                    "initial": "J.B.",
                    "last": "Cadorna-Carlos"
                },
                {
                    "first": "Terry",
                    "initial": "T.",
                    "last": "Nolan"
                },
                {
                    "first": "Charissa Fay",
                    "initial": "C.F.",
                    "last": "Borja-Tabora"
                },
                {
                    "first": "Jaime",
                    "initial": "J.",
                    "last": "Santos"
                },
                {
                    "first": "M. Cecilia",
                    "initial": "M.C.",
                    "last": "Montalban"
                },
                {
                    "first": "Ferdinandus J.",
                    "initial": "F.J.",
                    "last": "de Looze"
                },
                {
                    "first": "Peter",
                    "initial": "P.",
                    "last": "Eizenberg"
                },
                {
                    "first": "Stephen",
                    "initial": "S.",
                    "last": "Hall"
                },
                {
                    "first": "Martin",
                    "initial": "M.",
                    "last": "Dupuy"
                },
                {
                    "first": "Yanee",
                    "initial": "Y.",
                    "last": "Hutagalung"
                },
                {
                    "first": "St\u00e9phanie",
                    "initial": "S.",
                    "last": "P\u00e9pin"
                },
                {
                    "first": "Melanie",
                    "initial": "M.",
                    "last": "Saville"
                }
            ],
            "doi": "10.1016/j.vaccine.2015.03.065",
            "firstpage": "2485",
            "issn": "0264410X",
            "lastpage": "2492",
            "pmid": "25843270",
            "pub_year": 2015,
            "title": "Safety, immunogenicity, and lot-to-lot consistency of a quadrivalent inactivated influenza vaccine in children, adolescents, and adults: A randomized, controlled, phase III trial",
            "volume": "33"
        },
        "b0145": {
            "authors": [
                {
                    "first": "R. A.",
                    "initial": "R.A.",
                    "last": "Levandowski"
                },
                {
                    "first": "H. L.",
                    "initial": "H.L.",
                    "last": "Regnery"
                },
                {
                    "first": "E.",
                    "initial": "E.",
                    "last": "Staton"
                },
                {
                    "first": "B. G.",
                    "initial": "B.G.",
                    "last": "Burgess"
                },
                {
                    "first": "M. S.",
                    "initial": "M.S.",
                    "last": "Williams"
                },
                {
                    "first": "J. R.",
                    "initial": "J.R.",
                    "last": "Groothuis"
                }
            ],
            "firstpage": "1031",
            "issn": "00314005",
            "lastpage": "1036",
            "pmid": "1945607",
            "pub_year": 1991,
            "title": "Antibody responses to influenza B viruses in immunologically unprimed children",
            "volume": "88"
        },
        "b0150": {
            "authors": [
                {
                    "first": "Danuta M.",
                    "initial": "D.M.",
                    "last": "Skowronski"
                },
                {
                    "first": "Travis S.",
                    "initial": "T.S.",
                    "last": "Hottes"
                },
                {
                    "first": "Gaston",
                    "initial": "G.",
                    "last": "De Serres"
                },
                {
                    "first": "Brian J.",
                    "initial": "B.J.",
                    "last": "Ward"
                },
                {
                    "first": "Naveed Z.",
                    "initial": "N.Z.",
                    "last": "Janjua"
                },
                {
                    "first": "Suzana",
                    "initial": "S.",
                    "last": "Sabaiduc"
                },
                {
                    "first": "Tracy",
                    "initial": "T.",
                    "last": "Chan"
                },
                {
                    "first": "Martin",
                    "initial": "M.",
                    "last": "Petric"
                }
            ],
            "doi": "10.1097/INF.0b013e31822db4dc",
            "firstpage": "833",
            "issn": "08913668",
            "lastpage": "839",
            "pmid": "21857263",
            "pub_year": 2011,
            "title": "Influenza B/Victoria antigen induces strong recall of B/Yamagata but lower B/Victoria response in children primed with two doses of b/Yamagata",
            "volume": "30"
        },
        "b0155": {
            "authors": [
                {
                    "first": "Emanuele",
                    "initial": "E.",
                    "last": "Montomoli"
                },
                {
                    "first": "Alessandro",
                    "initial": "A.",
                    "last": "Torelli"
                },
                {
                    "first": "Ilaria",
                    "initial": "I.",
                    "last": "Manini"
                },
                {
                    "first": "Elena",
                    "initial": "E.",
                    "last": "Gianchecchi"
                }
            ],
            "doi": "10.3390/vaccines6010014",
            "issn": "2076393X",
            "pub_year": 2018,
            "title": "Immunogenicity and safety of the new inactivated quadrivalent influenza vaccine vaxigrip tetra: Preliminary results in children \u22656 months and older adults",
            "volume": "6"
        },
        "b0160": {
            "authors": [
                {
                    "first": "Geoffrey J.",
                    "initial": "G.J.",
                    "last": "Gorse"
                },
                {
                    "first": "Ann R.",
                    "initial": "A.R.",
                    "last": "Falsey"
                },
                {
                    "first": "Ayca",
                    "initial": "A.",
                    "last": "Ozol-Godfrey"
                },
                {
                    "first": "Victoria",
                    "initial": "V.",
                    "last": "Landolfi"
                },
                {
                    "first": "Peter H.",
                    "initial": "P.H.",
                    "last": "Tsang"
                }
            ],
            "doi": "10.1016/j.vaccine.2015.01.025",
            "firstpage": "1151",
            "issn": "0264410X",
            "lastpage": "1159",
            "pmid": "25613721",
            "pub_year": 2015,
            "title": "Safety and immunogenicity of a quadrivalent intradermal influenza vaccine in adults",
            "volume": "33"
        },
        "b0165": {
            "authors": [
                {
                    "first": "Wendy A.",
                    "initial": "W.A.",
                    "last": "Keitel"
                },
                {
                    "first": "Thomas R.",
                    "initial": "T.R.",
                    "last": "Cate"
                },
                {
                    "first": "Robert B.",
                    "initial": "R.B.",
                    "last": "Couch"
                },
                {
                    "first": "Linda L.",
                    "initial": "L.L.",
                    "last": "Huggins"
                },
                {
                    "first": "Kenneth R.",
                    "initial": "K.R.",
                    "last": "Hess"
                }
            ],
            "doi": "10.1016/S0264-410X(97)00003-0",
            "firstpage": "1114",
            "issn": "0264410X",
            "lastpage": "1122",
            "pmid": "9269055",
            "pub_year": 1997,
            "title": "Efficacy of repeated annual immunization with inactivated influenza virus vaccines over a five year period",
            "volume": "15"
        },
        "b0170": {
            "authors": [
                {
                    "first": "Sanae",
                    "initial": "S.",
                    "last": "Sasaki"
                },
                {
                    "first": "Xiao Song",
                    "initial": "X.S.",
                    "last": "He"
                },
                {
                    "first": "Tyson H.",
                    "initial": "T.H.",
                    "last": "Holmes"
                },
                {
                    "first": "Cornelia L.",
                    "initial": "C.L.",
                    "last": "Dekker"
                },
                {
                    "first": "George W.",
                    "initial": "G.W.",
                    "last": "Kemble"
                },
                {
                    "first": "Ann M.",
                    "initial": "A.M.",
                    "last": "Arvin"
                },
                {
                    "first": "Harry B.",
                    "initial": "H.B.",
                    "last": "Greenberg"
                }
            ],
            "doi": "10.1371/journal.pone.0002975",
            "issn": "19326203",
            "pmid": "18714352",
            "pub_year": 2008,
            "title": "Influence of prior influenza vaccination on antibody and B-cell responses",
            "volume": "3"
        },
        "b0175": {
            "authors": [
                {
                    "first": "Nizar",
                    "initial": "N.",
                    "last": "Souayah"
                },
                {
                    "first": "Senda",
                    "initial": "S.",
                    "last": "Ajroud-Driss"
                },
                {
                    "first": "Howard W.",
                    "initial": "H.W.",
                    "last": "Sander"
                },
                {
                    "first": "Thomas H.",
                    "initial": "T.H.",
                    "last": "Brannagan"
                },
                {
                    "first": "Arthur P.",
                    "initial": "A.P.",
                    "last": "Hays"
                },
                {
                    "first": "Russell L.",
                    "initial": "R.L.",
                    "last": "Chin"
                }
            ],
            "doi": "10.1016/j.vaccine.2009.09.077",
            "firstpage": "7322",
            "issn": "0264410X",
            "lastpage": "7325",
            "pmid": "19808027",
            "pub_year": 2009,
            "title": "Small fiber neuropathy following vaccination for rabies, varicella or Lyme disease",
            "volume": "27"
        },
        "b0180": {
            "authors": [
                {
                    "first": "Maurice",
                    "initial": "M.",
                    "last": "Sopacua"
                },
                {
                    "first": "Janneke G.J.",
                    "initial": "J.G.J.",
                    "last": "Hoeijmakers"
                },
                {
                    "first": "Ingemar S.J.",
                    "initial": "I.S.J.",
                    "last": "Merkies"
                },
                {
                    "first": "Giuseppe",
                    "initial": "G.",
                    "last": "Lauria"
                },
                {
                    "first": "Stephen G.",
                    "initial": "S.G.",
                    "last": "Waxman"
                },
                {
                    "first": "Catharina G.",
                    "initial": "C.G.",
                    "last": "Faber"
                }
            ],
            "doi": "10.1111/jns.12298",
            "firstpage": "19",
            "issn": "10859489",
            "lastpage": "33",
            "pmid": "30569495",
            "pub_year": 2019,
            "title": "Small-fiber neuropathy: Expanding the clinical pain universe",
            "volume": "24"
        },
        "b0185": null
    },
    "body_text": [
        {
            "endOffset": 30331,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0045",
            "sentence": "Ten two-fold dilutions of each sera were mixed and incubated with 4 hemagglutination units/25 \u00b5L of influenza virus.",
            "startOffset": 30215,
            "title": "Measurement of HAI antibody titers"
        },
        {
            "endOffset": 46879,
            "parents": [],
            "secId": "s0135",
            "sentence": "The current study, performed in 2670 adults \u226565 years of age, showed that a quadrivalent formulation of the high-dose vaccine, IIV4-HD, induced HAI antibody responses that were non-inferior to responses induced by IIV3-HD for the three shared strains and superior responses for the additional B-lineage strain.",
            "startOffset": 46569,
            "title": "Discussion"
        },
        {
            "endOffset": 27661,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "The study enrolled adults \u226565 years of age who were not vaccinated against influenza in the previous 6 months.",
            "startOffset": 27551,
            "title": "Subjects"
        },
        {
            "endOffset": 28771,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "The volume administered was 0.7 mL for IIV4-HD and 0.5 mL for IIV3-HD1 and IIV3-HD2.",
            "startOffset": 28687,
            "title": "Vaccines"
        },
        {
            "endOffset": 28103,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "IIV4-HD contained the World Health Organization (WHO)/US Food and Drug Administration (FDA)-recommended strains for the 2017\u20132018 Northern Hemisphere influenza season (batch UD19520).",
            "startOffset": 27920,
            "title": "Vaccines"
        },
        {
            "endOffset": 44404,
            "parents": [
                {
                    "id": "s0080",
                    "title": "Results"
                },
                {
                    "id": "s0090",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0120",
            "sentence": "For the A/H1N1 and A/H3N2 strains, post-vaccination seroneutralisation and anti-neuraminidase GMTs and GMTRs were similar for IIV4-HD and the pooled IIV3-HDs.",
            "startOffset": 44246,
            "title": "Seroneutralisation and anti-neuraminidase antibody responses"
        },
        {
            "endOffset": 29947,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0045",
            "sentence": "All subjects were to provide a pre-vaccination (baseline) blood sample at day 0 and a post-vaccination blood sample at the end of the active phase of the trial (day 28\u201335) for HAI testing.",
            "startOffset": 29759,
            "title": "Measurement of HAI antibody titers"
        },
        {
            "endOffset": 45348,
            "parents": [
                {
                    "id": "s0080",
                    "title": "Results"
                }
            ],
            "secId": "s0125",
            "sentence": "Proportions reporting all injection-site reactions, as well as myalgia, shivering, and headache were higher for IIV4-HD than for IIV3-HD.",
            "startOffset": 45211,
            "title": "Solicited reactions"
        },
        {
            "endOffset": 45562,
            "parents": [
                {
                    "id": "s0080",
                    "title": "Results"
                }
            ],
            "secId": "s0125",
            "sentence": "Most reactions began within 3 days of vaccination (Supplementary Table 8) and resolved within 3 days of onset (Supplementary Table 9).",
            "startOffset": 45428,
            "title": "Solicited reactions"
        },
        {
            "endOffset": 48567,
            "parents": [],
            "refoffsets": {
                "b0155": {
                    "endOffset": 48287,
                    "startOffset": 48283
                },
                "b0160": {
                    "endOffset": 48339,
                    "startOffset": 48335
                }
            },
            "secId": "s0135",
            "sentence": "This has been observed previously with the standard-dose quadrivalent influenza vaccine [31] and quadrivalent intradermal influenza vaccine [32] but is not considered to be clinically relevant because the HAI GMTs and seroconversion rates for the quadrivalent vaccines were statistically non-inferior to those induced by the trivalent vaccines containing the same strains.",
            "startOffset": 48195,
            "title": "Discussion"
        },
        {
            "endOffset": 31609,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0050",
            "sentence": "Serum samples, quality control sera, and previously titred influenza virus were added into duplicate wells of a fetuin-coated 96-well plate and incubated overnight.",
            "startOffset": 31445,
            "title": "Measurement of neuraminidase antibody titers"
        },
        {
            "endOffset": 34807,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0065",
            "sentence": "SAEs were collected up to end of the study (day 180\u2013194).",
            "startOffset": 34750,
            "title": "Unsolicited AEs"
        },
        {
            "endOffset": 47696,
            "parents": [],
            "refoffsets": {
                "b0100": {
                    "endOffset": 47628,
                    "startOffset": 47621
                },
                "b0140": {
                    "endOffset": 47628,
                    "startOffset": 47621
                }
            },
            "secId": "s0135",
            "sentence": "In that study, the current one, and some others examining standard-dose trivalent influenza vaccines [20,28], significant low-level B-strain cross-reactivity has been detected.",
            "startOffset": 47520,
            "title": "Discussion"
        },
        {
            "endOffset": 23268,
            "parents": [],
            "refoffsets": {
                "b0020": {
                    "endOffset": 23267,
                    "startOffset": 23262
                },
                "b0025": {
                    "endOffset": 23267,
                    "startOffset": 23262
                },
                "b0030": {
                    "endOffset": 23267,
                    "startOffset": 23262
                }
            },
            "secId": "s0005",
            "sentence": "Approaches to improve immune responses have included increasing the antigen dose, including an adjuvant, and exploring alternative routes of administration [4\u20136].",
            "startOffset": 23106,
            "title": "Introduction"
        },
        {
            "endOffset": 39809,
            "parents": [
                {
                    "id": "s0080",
                    "title": "Results"
                }
            ],
            "secId": "s0085",
            "sentence": "The study included 2670 adults \u226565 years of age enrolled between September 8, 2017 and September 15, 2017.",
            "startOffset": 39703,
            "title": "Subjects"
        },
        {
            "endOffset": 50094,
            "parents": [],
            "secId": "s0135",
            "sentence": "The study should be interpreted in the context of certain limitations of the study design.",
            "startOffset": 50004,
            "title": "Discussion"
        },
        {
            "endOffset": 26383,
            "parents": [],
            "secId": "s0005",
            "sentence": "The current study assessed the safety and immunogenicity of a quadrivalent formulation of the high-dose split-virion inactivated influenza vaccine (IIV4-HD) in adults \u226565 years of age.",
            "startOffset": 26199,
            "title": "Introduction"
        },
        {
            "endOffset": 40217,
            "parents": [
                {
                    "id": "s0080",
                    "title": "Results"
                }
            ],
            "secId": "s0085",
            "sentence": "The most common reason for early discontinuation was a protocol deviation (did not complete the day 28\u201335 visit [n = 6] and participating in another clinical trial [n = 1]).",
            "startOffset": 40044,
            "title": "Subjects"
        },
        {
            "endOffset": 32134,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0050",
            "sentence": "The lower limit of quantitation was the reciprocal of the lowest dilution used in the assay (1:10).",
            "startOffset": 32035,
            "title": "Measurement of neuraminidase antibody titers"
        },
        {
            "endOffset": 36751,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0070",
            "sentence": "Non-inferiority of IIV4-HD to each IIV3-HD group in terms of HAI GMTs was demonstrated if, for each of the three common strains, the lower limit of the 2-sided 95% CI for the difference of the log10 (GMT) for IIV4-HD vs. IIV3-HD was >log10 (1/1.5).",
            "startOffset": 36503,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 39852,
            "parents": [
                {
                    "id": "s0080",
                    "title": "Results"
                }
            ],
            "secId": "s0085",
            "sentence": "The study was completed on April 19, 2018.",
            "startOffset": 39810,
            "title": "Subjects"
        },
        {
            "endOffset": 48855,
            "parents": [],
            "refoffsets": {
                "b0165": {
                    "endOffset": 48760,
                    "startOffset": 48756
                },
                "b0170": {
                    "endOffset": 48854,
                    "startOffset": 48850
                }
            },
            "secId": "s0135",
            "sentence": "This phenomenon is well known for influenza vaccines [33] and may be due, in part, to absorption of antigen by circulating pre-existing antibodies [34].",
            "startOffset": 48703,
            "title": "Discussion"
        },
        {
            "endOffset": 33763,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0060",
            "sentence": "Fever was scored as grade 1 if 100.4\u2013101.1\u00b0F (38.0\u201338.4 \u00b0C), grade 2 if 101.2\u2013102.0\u00b0F (38.5\u201338.9 \u00b0C), and grade 3 if \u2265102.1\u00b0F (\u226539.0 \u00b0C).",
            "startOffset": 33626,
            "title": "Solicited reactions"
        },
        {
            "endOffset": 34749,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0065",
            "sentence": "Any unsolicited systemic AEs occurring during the first 30 min after vaccination were recorded as immediate unsolicited systemic AEs.",
            "startOffset": 34616,
            "title": "Unsolicited AEs"
        },
        {
            "endOffset": 43504,
            "parents": [
                {
                    "id": "s0080",
                    "title": "Results"
                },
                {
                    "id": "s0090",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0115",
            "sentence": "In all vaccine groups and for all strains, at least 91.6% of subjects were seropositive before vaccination as defined by a HAI titer \u226510 (Table 4).",
            "startOffset": 43357,
            "title": "Influence of baseline antibodies and previous vaccination on post-vaccination HAI antibody responses"
        },
        {
            "endOffset": 28309,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "IIV3-HD1 (Fluzone High-Dose, Sanofi Pasteur) was the licensed 2017\u20132018 Northern Hemisphere formulation and contained the WHO/FDA-recommended A/H1N1, A/H3N2, and B Victoria-lineage strains (batch UD19521).",
            "startOffset": 28104,
            "title": "Vaccines"
        },
        {
            "endOffset": 24929,
            "parents": [],
            "refoffsets": {
                "b0040": {
                    "endOffset": 24928,
                    "startOffset": 24925
                }
            },
            "secId": "s0005",
            "sentence": "Based on results from this trial, IIV3-HD was predicted to be cost-saving compared to IIV3-SD, mostly due to reduced hospitalizations [8].",
            "startOffset": 24791,
            "title": "Introduction"
        },
        {
            "endOffset": 38413,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0070",
            "sentence": "Statistical analyses were performed using SAS version 9.4 or later (SAS Institute, Cary, NC, USA).",
            "startOffset": 38315,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 31296,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0050",
            "sentence": "Neuraminidase antibody titers were measured as an exploratory endpoint.",
            "startOffset": 31225,
            "title": "Measurement of neuraminidase antibody titers"
        },
        {
            "endOffset": 37542,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0070",
            "sentence": "Sensitivity of non-inferiority of HAI GMTs was assessed by analysis of covariance of post-vaccination HAI titers adjusted for baseline HAI titers.",
            "startOffset": 37396,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 51491,
            "parents": [],
            "refoffsets": {
                "b0045": {
                    "endOffset": 51490,
                    "startOffset": 51484
                },
                "b0050": {
                    "endOffset": 51490,
                    "startOffset": 51484
                },
                "b0055": {
                    "endOffset": 51490,
                    "startOffset": 51484
                },
                "b0060": {
                    "endOffset": 51490,
                    "startOffset": 51484
                },
                "b0065": {
                    "endOffset": 51490,
                    "startOffset": 51484
                },
                "b0070": {
                    "endOffset": 51490,
                    "startOffset": 51484
                },
                "b0075": {
                    "endOffset": 51490,
                    "startOffset": 51484
                }
            },
            "secId": "s0135",
            "sentence": "Thus, transitioning from the trivalent formulation, IIV3-HD, to the quadrivalent formulation, IIV4-HD, is expected to further extend the benefits of the high-dose vaccine, which include improved protection against influenza infection and influenza-related cardio-respiratory events, death, and health care utilization [9\u201315].",
            "startOffset": 51166,
            "title": "Discussion"
        },
        {
            "endOffset": 42076,
            "parents": [
                {
                    "id": "s0080",
                    "title": "Results"
                },
                {
                    "id": "s0090",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0100",
            "sentence": "Seroconversion rates for the A/H1N1 strain were 50.4% (95%CI: 48.0%\u201352.8%) for IIV4-HD and 53.7% (95%CI: 50.2%\u201357.1%) for the pooled IIV3-HDs.",
            "startOffset": 41934,
            "title": "HAI antibody response to influenza A strains"
        },
        {
            "endOffset": 28686,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "The vaccines, their antigen content, and the volumes injected are summarized in Table 1.",
            "startOffset": 28598,
            "title": "Vaccines"
        },
        {
            "endOffset": 41621,
            "parents": [
                {
                    "id": "s0080",
                    "title": "Results"
                },
                {
                    "id": "s0090",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0095",
            "sentence": "Thus, the primary immunogenicity objective of non-inferiority for all four strains for both GMTs and seroconversion rates was confirmed.",
            "startOffset": 41485,
            "title": "Non-inferiority and superiority of HAI GMTs and seroconversion rates"
        },
        {
            "endOffset": 45210,
            "parents": [
                {
                    "id": "s0080",
                    "title": "Results"
                }
            ],
            "secId": "s0125",
            "sentence": "The most common solicited reactions for both IIV3-HD and IIV4-HD were injection-site pain, myalgia, malaise, and headache (Fig. 5).",
            "startOffset": 45079,
            "title": "Solicited reactions"
        },
        {
            "endOffset": 49770,
            "parents": [],
            "secId": "s0135",
            "sentence": "A single AE of special interest, small-fiber neuropathy in a subject 42 days after vaccination with IIV4-HD, was recorded by the investigator as possibly related to the study vaccine.",
            "startOffset": 49587,
            "title": "Discussion"
        },
        {
            "endOffset": 46028,
            "parents": [
                {
                    "id": "s0080",
                    "title": "Results"
                }
            ],
            "secId": "s0130",
            "sentence": "The event was a grade 2 (moderate severity) small-fiber neuropathy involving both sensory and autonomic fibers diagnosed 42 days after vaccination with IIV4-HD.",
            "startOffset": 45868,
            "title": "Unsolicited AEs"
        },
        {
            "endOffset": 43730,
            "parents": [
                {
                    "id": "s0080",
                    "title": "Results"
                },
                {
                    "id": "s0090",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0115",
            "sentence": "For all strains in all vaccine groups except B Victoria lineage for IIV3-HD1, post-vaccination HAI GMTs were higher and seroconversion rates lower for subjects who were seropositive at baseline (Supplementary Tables 2 and 3).",
            "startOffset": 43505,
            "title": "Influence of baseline antibodies and previous vaccination on post-vaccination HAI antibody responses"
        },
        {
            "endOffset": 25677,
            "parents": [],
            "refoffsets": {
                "b0080": {
                    "endOffset": 25676,
                    "startOffset": 25669
                },
                "b0085": {
                    "endOffset": 25676,
                    "startOffset": 25669
                }
            },
            "secId": "s0005",
            "sentence": "Increased hemagglutination inhibition, seroneutralisation, and anti-neuraminidase antibody titers further support the improved efficacy of IIV3-HD [16,17].",
            "startOffset": 25522,
            "title": "Introduction"
        },
        {
            "endOffset": 26706,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "This was a randomized, modified double-blind, active-controlled, multicenter trial in adults \u226565 years of age conducted between September 2017 and April 2018 at 35 sites in the US (NCT03282240)2.",
            "startOffset": 26414,
            "title": "Overall study design"
        },
        {
            "endOffset": 43100,
            "parents": [
                {
                    "id": "s0080",
                    "title": "Results"
                },
                {
                    "id": "s0090",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0110",
            "sentence": "For the B Yamagata-lineage strain, the post-vaccination HAI GMT was similar for IIV4-HD (578 [95%CI: 547\u2013612]) and IIV3-HD containing the B Yamagata-lineage strain (IIV3-HD2) (580 [95%CI: 519\u2013649]) but lower for IIV3-HD containing the B Victoria-lineage strain (IIV3-HD1) (282 [95%CI: 250\u2013318]) (Table 4).",
            "startOffset": 42795,
            "title": "HAI antibody response to the B Yamagata-lineage strain"
        },
        {
            "endOffset": 45750,
            "parents": [
                {
                    "id": "s0080",
                    "title": "Results"
                }
            ],
            "secId": "s0130",
            "sentence": "For unsolicited AEs, AEs leading to study discontinuation, SAEs, deaths, and AEs of special interest, proportions were similar between IIV4-HD and the IIV3-HDs (Table 5).",
            "startOffset": 45580,
            "title": "Unsolicited AEs"
        },
        {
            "endOffset": 32952,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0055",
            "sentence": "The lower limit of quantitation was the reciprocal of the lowest dilution used in the assay (1:10).",
            "startOffset": 32853,
            "title": "Measurement of seroneutralisation antibody titers"
        },
        {
            "endOffset": 27110,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "The primary objectives were to assess the safety of IIV4-HD as measured by solicited reactions and unsolicited adverse events (AEs) and to demonstrate that IIV4-HD induces hemagglutination inhibition (HAI) geometric mean titers (GMTs) and seroconversion rates that are non-inferior to responses induced by the licensed IIV3-HD (IIV3-HD1) and IIV3-HD containing the alternate B-lineage strain (IIV3-HD2).",
            "startOffset": 26707,
            "title": "Overall study design"
        },
        {
            "endOffset": 36129,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0070",
            "sentence": "Seroneutralisation and anti-neuraminidase antibody responses were measured in the expanded immunogenicity subset, which was defined as all subjects in the full analysis set who were randomized to the subset and who had a post-vaccination seroneutralisation assay result for at least one strain.",
            "startOffset": 35835,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 38486,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0070",
            "sentence": "Missing data were not imputed, and no search for outliers was performed.",
            "startOffset": 38414,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 35706,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0070",
            "sentence": "The full analysis set was defined as all subjects who received the trial vaccine and had a post-vaccination blood sample HAI result for at least one strain.",
            "startOffset": 35550,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 39253,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0075",
            "sentence": "This assumed (i) an 8% attrition rate in the per-protocol analysis set, (ii) seroconversion rates of 45% for the A/H1N1 strain, 70% for the A/H3N2 strain, and 40% for both B (B1 and B2) strains, and (iii) standard deviations for HAI GMTs of 0.63 for both A strains and 0.55 for both B strains.3",
            "startOffset": 38838,
            "title": "Sample size estimation"
        },
        {
            "endOffset": 49509,
            "parents": [],
            "secId": "s0135",
            "sentence": "However, firm conclusions about rates of individual safety events cannot be drawn because the study was not designed or powered to make comparisons.",
            "startOffset": 49361,
            "title": "Discussion"
        },
        {
            "endOffset": 40783,
            "parents": [
                {
                    "id": "s0080",
                    "title": "Results"
                }
            ],
            "secId": "s0085",
            "sentence": "In all three groups, over 70% were vaccinated the previous year for influenza.",
            "startOffset": 40705,
            "title": "Subjects"
        },
        {
            "endOffset": 47084,
            "parents": [],
            "secId": "s0135",
            "sentence": "IIV4-HD also induced seroneutralisation and anti-neuraminidase antibody responses that were similar to those induced by IIV3-HD for the three shared strains and higher for the additional B-lineage strain.",
            "startOffset": 46880,
            "title": "Discussion"
        },
        {
            "endOffset": 31444,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "refoffsets": {
                "b0105": {
                    "endOffset": 31443,
                    "startOffset": 31436
                },
                "b0110": {
                    "endOffset": 31443,
                    "startOffset": 31436
                }
            },
            "secId": "s0050",
            "sentence": "H6Nx virus reassortants were used in the assay as a source of neuraminidase from A/California/7/2009 (H1N1) and A/Victoria/361/2011 (H3N2) [21,22].",
            "startOffset": 31297,
            "title": "Measurement of neuraminidase antibody titers"
        },
        {
            "endOffset": 47790,
            "parents": [],
            "refoffsets": {
                "b0145": {
                    "endOffset": 47789,
                    "startOffset": 47782
                },
                "b0150": {
                    "endOffset": 47789,
                    "startOffset": 47782
                }
            },
            "secId": "s0135",
            "sentence": "This has also been observed in children vaccinated with trivalent influenza vaccines [29,30].",
            "startOffset": 47697,
            "title": "Discussion"
        },
        {
            "endOffset": 50179,
            "parents": [],
            "secId": "s0135",
            "sentence": "Importantly, the population was limited to healthy, community-dwelling older adults.",
            "startOffset": 50095,
            "title": "Discussion"
        },
        {
            "endOffset": 47332,
            "parents": [],
            "secId": "s0135",
            "sentence": "Thus, despite the higher dose of antigen, adding a second B strain to the high-dose split-virion influenza vaccine did not compromise the immunogenicity induced by the other three strains or limit the immune response to the added B-lineage strain.",
            "startOffset": 47085,
            "title": "Discussion"
        },
        {
            "endOffset": 36361,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "refoffsets": {
                "b0125": {
                    "endOffset": 36290,
                    "startOffset": 36286
                }
            },
            "secId": "s0070",
            "sentence": "The 95% confidence intervals (CIs) were calculated using normal approximation of log-transformed titers for ratio of GMTs and using the Wilson score method [25] without continuity correction for differences in seroconversion rates.",
            "startOffset": 36130,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 37770,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0070",
            "sentence": "Superiority was assessed as a secondary objective and was demonstrated if the 2-sided 95% CI for the difference of the log10 (GMT) for IIV4-HD vs. IIV3-HD was >log10 (1.5) and for the difference of seroconversion rates was >10%.",
            "startOffset": 37542,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 26036,
            "parents": [],
            "refoffsets": {
                "b0090": {
                    "endOffset": 26035,
                    "startOffset": 26031
                }
            },
            "secId": "s0005",
            "sentence": "As a result, the B-lineage strain in trivalent vaccines and the dominant circulating B-lineage strain have differed in about 25% of influenza seasons [18].",
            "startOffset": 25881,
            "title": "Introduction"
        },
        {
            "endOffset": 44930,
            "parents": [
                {
                    "id": "s0080",
                    "title": "Results"
                },
                {
                    "id": "s0090",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0120",
            "sentence": "Seroneutralisation post-/pre-vaccination GMTRs for IIV4-HD were 5.40 (95%CI: 3.90\u20137.48) for A/H1N1, 2.83 (95%CI: 2.31\u20133.46) for A/H3N2, 2.81 (95%CI: 2.21\u20133.58) for B Victoria, and 3.51 (95%CI: 2.80\u20134.39) for B Yamagata.",
            "startOffset": 44711,
            "title": "Seroneutralisation and anti-neuraminidase antibody responses"
        },
        {
            "endOffset": 36502,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0070",
            "sentence": "The primary objective of non-inferiority used margins of 1.5 for GMTs and 10% for seroconversion rates, which were agreed on with the US FDA.",
            "startOffset": 36361,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 50004,
            "parents": [],
            "refoffsets": {
                "b0175": {
                    "endOffset": 50003,
                    "startOffset": 49996
                },
                "b0180": {
                    "endOffset": 50003,
                    "startOffset": 49996
                }
            },
            "secId": "s0135",
            "sentence": "The subject also had a recent viral infection and was diagnosed with vitamin B12 deficiency, either of which might have caused the event [35,36].",
            "startOffset": 49859,
            "title": "Discussion"
        },
        {
            "endOffset": 40489,
            "parents": [
                {
                    "id": "s0080",
                    "title": "Results"
                }
            ],
            "secId": "s0085",
            "sentence": "Baseline characteristics were similar in the three vaccine groups (Table 2).",
            "startOffset": 40413,
            "title": "Subjects"
        },
        {
            "endOffset": 32998,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0055",
            "sentence": "Titers below this level were reported as <10.",
            "startOffset": 32953,
            "title": "Measurement of seroneutralisation antibody titers"
        },
        {
            "endOffset": 33361,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0060",
            "sentence": "Injection-site reactions recorded included pain, erythema, swelling, induration, and bruising.",
            "startOffset": 33267,
            "title": "Solicited reactions"
        },
        {
            "endOffset": 28959,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "Subjects were randomized by interactive response technology in a 4:1:1 ratio to receive a single intramuscular injection in the upper arm of IIV4-HD, IIV3-HD1, or IIV3-HD2.",
            "startOffset": 28787,
            "title": "Randomization"
        },
        {
            "endOffset": 38837,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0075",
            "sentence": "The non-inferiority margins were defined as 1.5 for GMTs and 10% for seroconversion rates.",
            "startOffset": 38747,
            "title": "Sample size estimation"
        },
        {
            "endOffset": 39684,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0075",
            "sentence": "Based on the planned sample size of 2616, there was 55.4% power to conclude the superiority of each B strain comparing IIV4-HD groups versus either the IIV3-HD1 or IIV3-HD2 group assuming (i) a 5% attrition rate in the full analysis set, (ii) a GMT ratio of 1.8 with a standard deviation of 0.55, (iii) a seroconversion rate of 8% increase in the group without the B strain and a 22% increase in the group with the B strain.4",
            "startOffset": 39253,
            "title": "Sample size estimation"
        },
        {
            "endOffset": 43922,
            "parents": [
                {
                    "id": "s0080",
                    "title": "Results"
                },
                {
                    "id": "s0090",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0115",
            "sentence": "Post-vaccination HAI GMTs and seroconversion rates were generally lower in subjects who were vaccinated for influenza the previous year than those who were not (Supplementary Tables 4 and 5).",
            "startOffset": 43731,
            "title": "Influence of baseline antibodies and previous vaccination on post-vaccination HAI antibody responses"
        },
        {
            "endOffset": 33625,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0060",
            "sentence": "Injection-site erythema, swelling, induration and bruising were scored as grade 1 if 25\u201350 mm in diameter, grade 2 if 51\u2013100 mm in diameter, and grade 3 if >100 mm in diameter.",
            "startOffset": 33449,
            "title": "Solicited reactions"
        },
        {
            "endOffset": 25880,
            "parents": [],
            "secId": "s0005",
            "sentence": "For the last two decades, two distinct B influenza lineages (Victoria and Yamagata) have co-circulated, making it difficult to predict which of the two B lineages will predominate during the next season.",
            "startOffset": 25677,
            "title": "Introduction"
        },
        {
            "endOffset": 37211,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0070",
            "sentence": "For non-inferiority comparisons, the IIV3 comparator was the pooled IIV3-HD1 and IIV3-HD2 groups for the A/H1N1 and A/H3N2 strains; IIV3-HD1 for the B Victoria-lineage strain; and IIV-HD2 for the B Yamagata-lineage strain.",
            "startOffset": 36989,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 50908,
            "parents": [],
            "refoffsets": {
                "b0030": {
                    "endOffset": 50749,
                    "startOffset": 50743
                },
                "b0080": {
                    "endOffset": 50749,
                    "startOffset": 50743
                },
                "b0185": {
                    "endOffset": 50858,
                    "startOffset": 50854
                }
            },
            "secId": "s0135",
            "sentence": "Finally, based on safety data collected from more than 25,000 individuals during clinical development of IIV3-HD [6,16] and pharmacovigilance data collected from more than 115 million doses of IIV3-HD distributed since 2009 [37], no safety concerns with IIV4-HD are anticipated.",
            "startOffset": 50630,
            "title": "Discussion"
        },
        {
            "endOffset": 29067,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "Permuted block randomization with block sizes 6 and 12 was applied for all subjects within strata by sites.",
            "startOffset": 28960,
            "title": "Randomization"
        },
        {
            "endOffset": 48089,
            "parents": [],
            "secId": "s0135",
            "sentence": "Adding a second B-lineage strain in IIV4-HD should therefore broaden protection against influenza B infection in adults \u226565 years of age.",
            "startOffset": 47952,
            "title": "Discussion"
        },
        {
            "endOffset": 44245,
            "parents": [
                {
                    "id": "s0080",
                    "title": "Results"
                },
                {
                    "id": "s0090",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0120",
            "sentence": "In a random subset of approximately 100 subjects from each group, seroneutralisation was measured for all four vaccine strains (Fig. 3 and Supplementary Table 6) and anti-neuraminidase antibody titers for the two A strains (Fig. 4 and Supplementary Table 7).",
            "startOffset": 43987,
            "title": "Seroneutralisation and anti-neuraminidase antibody responses"
        },
        {
            "endOffset": 29258,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "In addition, approximately 100 subjects per treatment group were randomly selected by interactive response technology for measurement of neuraminidase and seroneutralisation antibody titers.",
            "startOffset": 29068,
            "title": "Randomization"
        },
        {
            "endOffset": 40043,
            "parents": [
                {
                    "id": "s0080",
                    "title": "Results"
                }
            ],
            "secId": "s0085",
            "sentence": "Of the 2670 enrolled subjects, 2654 completed the active study period (day 28\u201335).",
            "startOffset": 39961,
            "title": "Subjects"
        },
        {
            "endOffset": 32658,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0055",
            "sentence": "Viral nucleoprotein production was measured by enzyme-linked immunosorbent assay using a monoclonal antibody specific to either influenza A or influenza B nucleoprotein.",
            "startOffset": 32489,
            "title": "Measurement of seroneutralisation antibody titers"
        },
        {
            "endOffset": 36988,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0070",
            "sentence": "The non-inferiority of IIV4-HD to each IIV3-HD group in terms of seroconversion rates was demonstrated, if for each of the three common strains, the lower limit of the 2-sided 95% CI for the difference of seroconversion rates was >\u221210%.",
            "startOffset": 36752,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 29623,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0040",
            "sentence": "The study was modified double-blind, meaning that an unblinded administrator at each site administered the vaccine but that the investigators (or delegates) in charge of safety assessment, the trial staff who collected the safety data, the laboratory personnel who analyzed the blood samples, and the subjects did not know which product was administered.",
            "startOffset": 29269,
            "title": "Blinding"
        },
        {
            "endOffset": 31178,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0045",
            "sentence": "The primary endpoints for the evaluation of immunogenicity were HAI antibody titers obtained on day 28 and seroconversion, defined as either (i) a HAI titer <10 (1/dilution) at day 0 and a post-vaccination (day 28\u201335) HAI titer \u226540 or (ii) a HAI titer \u226510 at day 0 and a \u22654-fold increase in HAI titer between day 0 and post-vaccination.",
            "startOffset": 30842,
            "title": "Measurement of HAI antibody titers"
        },
        {
            "endOffset": 24490,
            "parents": [],
            "secId": "s0005",
            "sentence": "IIV3-HD contains 60 \u00b5g hemagglutinin per influenza strain, which is four times the antigen content of standard-dose inactivated influenza vaccines.",
            "startOffset": 24343,
            "title": "Introduction"
        },
        {
            "endOffset": 30521,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0045",
            "sentence": "A red blood cell suspension was added to the mixture and, following incubation, titers were recorded as the highest serum dilution in which complete inhibition of hemagglutination occurred.",
            "startOffset": 30332,
            "title": "Measurement of HAI antibody titers"
        },
        {
            "endOffset": 32180,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0050",
            "sentence": "Titers below this level were reported as <10.",
            "startOffset": 32135,
            "title": "Measurement of neuraminidase antibody titers"
        },
        {
            "endOffset": 27460,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0020",
            "sentence": "The study was approved by the independent ethics committee or institutional review board for each institution and was conducted in compliance with the standards established by the Declaration of Helsinki, International Conference for Harmonisation guidelines for Good Clinical Practice, and all local and national regulations and directives.",
            "startOffset": 27119,
            "title": "Ethics"
        },
        {
            "endOffset": 33448,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0060",
            "sentence": "Systemic reactions recorded included fever, headache, malaise, myalgia, and shivering.",
            "startOffset": 33362,
            "title": "Solicited reactions"
        },
        {
            "endOffset": 46569,
            "parents": [],
            "refoffsets": {
                "b0045": {
                    "endOffset": 46568,
                    "startOffset": 46559
                },
                "b0050": {
                    "endOffset": 46568,
                    "startOffset": 46559
                },
                "b0055": {
                    "endOffset": 46568,
                    "startOffset": 46559
                },
                "b0060": {
                    "endOffset": 46568,
                    "startOffset": 46559
                },
                "b0065": {
                    "endOffset": 46568,
                    "startOffset": 46559
                },
                "b0070": {
                    "endOffset": 46568,
                    "startOffset": 46559
                },
                "b0075": {
                    "endOffset": 46568,
                    "startOffset": 46559
                },
                "b0130": {
                    "endOffset": 46568,
                    "startOffset": 46559
                }
            },
            "secId": "s0135",
            "sentence": "Post-licensure studies have further demonstrated a benefit of IIV3-HD over IIV3-SD for serious influenza-related events and death [9\u201315,26].",
            "startOffset": 46429,
            "title": "Discussion"
        },
        {
            "endOffset": 35100,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0065",
            "sentence": "SAEs included any medical occurrence resulting in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or was an AE of special interest.",
            "startOffset": 34808,
            "title": "Unsolicited AEs"
        },
        {
            "endOffset": 47519,
            "parents": [],
            "refoffsets": {
                "b0135": {
                    "endOffset": 47518,
                    "startOffset": 47514
                }
            },
            "secId": "s0135",
            "sentence": "Similar findings were obtained in a study comparing the immunogenicity of standard-dose quadrivalent split-virion influenza vaccine (IIV4-SD) and IIV3-SDs in adults \u226565 years of age [27].",
            "startOffset": 47332,
            "title": "Discussion"
        },
        {
            "endOffset": 26198,
            "parents": [],
            "refoffsets": {
                "b0095": {
                    "endOffset": 26197,
                    "startOffset": 26193
                }
            },
            "secId": "s0005",
            "sentence": "To improve protection against influenza infection, quadrivalent influenza vaccines incorporating a strain from each B lineage have therefore been developed [19].",
            "startOffset": 26037,
            "title": "Introduction"
        },
        {
            "endOffset": 27855,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "Individuals were excluded if they had any condition or were receiving any treatment that, in the opinion of the investigator, could interfere with the trial conduct, completion, or assessments.",
            "startOffset": 27662,
            "title": "Subjects"
        },
        {
            "endOffset": 43252,
            "parents": [
                {
                    "id": "s0080",
                    "title": "Results"
                },
                {
                    "id": "s0090",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0110",
            "sentence": "Seroconversion rates were 46.6% (95%CI: 44.2%\u201349.0%) for IIV4-HD, 17.6% (95%CI: 14.1%\u201321.6%) for IIV3-HD1, and 48.4% (95%CI: 43.5%\u201353.2%) for IIV3-HD2.",
            "startOffset": 43101,
            "title": "HAI antibody response to the B Yamagata-lineage strain"
        },
        {
            "endOffset": 37913,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0070",
            "sentence": "For superiority comparisons, the IIV3 comparator was IIV3-HD1 for the B Yamagata-lineage strain and IIV-HD2 for the B Victoria-lineage strain.",
            "startOffset": 37771,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 27540,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0020",
            "sentence": "All subjects provided signed, informed consent before taking part in the study.",
            "startOffset": 27461,
            "title": "Ethics"
        },
        {
            "endOffset": 45057,
            "parents": [
                {
                    "id": "s0080",
                    "title": "Results"
                },
                {
                    "id": "s0090",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0120",
            "sentence": "Anti-neuraminidase post-/pre-vaccination GMTRs were 1.61 (95%CI: 1.44\u20131.81) for A/H1N1 and 2.12 (95%CI: 1.84\u20132.45) for A/H3N2.",
            "startOffset": 44931,
            "title": "Seroneutralisation and anti-neuraminidase antibody responses"
        },
        {
            "endOffset": 49360,
            "parents": [],
            "secId": "s0135",
            "sentence": "As expected with the higher dose of antigen in IIV4-HD, proportions of subjects reporting solicited injection-site reactions, and some solicited systemic reactions (myalgia, shivering, and headache) were slightly higher than with IIV3-HD, although the severity of solicited events and the severity and occurrence of unsolicited AEs did not appear to increase.",
            "startOffset": 49001,
            "title": "Discussion"
        },
        {
            "endOffset": 38746,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0075",
            "sentence": "A sample size of 2616 subjects was determined based on an overall power of 90% for demonstrating non-inferiority for both the HAI GMTs and seroconversion rates comparing IIV4-HD vs. IIV3-HD1 and/or IIV3-HD2 for all four virus strains.",
            "startOffset": 38512,
            "title": "Sample size estimation"
        },
        {
            "endOffset": 25271,
            "parents": [],
            "refoffsets": {
                "b0045": {
                    "endOffset": 25270,
                    "startOffset": 25267
                }
            },
            "secId": "s0005",
            "sentence": "A phase IV cluster-randomized trial in long-stay nursing home residents \u226565 years of age further showed that the risk of respiratory-related hospital admissions, pneumonia-related hospital admissions, and all-cause hospitalizations were lower in facilities where residents received IIV3-HD than in those where residents received IIV3-SD [9].",
            "startOffset": 24930,
            "title": "Introduction"
        },
        {
            "endOffset": 32034,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0050",
            "sentence": "The titer of each determination was the reciprocal of the last dilution with an optical density less than or equal to the midpoint between the mean optical density of the virus-only control wells and the mean optical density of the background wells on each plate.",
            "startOffset": 31771,
            "title": "Measurement of neuraminidase antibody titers"
        },
        {
            "endOffset": 31690,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0050",
            "sentence": "The plate was washed and incubated with peroxidase-conjugated peanut agglutinin.",
            "startOffset": 31610,
            "title": "Measurement of neuraminidase antibody titers"
        },
        {
            "endOffset": 47951,
            "parents": [],
            "refoffsets": {
                "b0145": {
                    "endOffset": 47950,
                    "startOffset": 47943
                },
                "b0150": {
                    "endOffset": 47950,
                    "startOffset": 47943
                }
            },
            "secId": "s0135",
            "sentence": "However, antibody titers induced by B-strain cross-reactivity have been suboptimal and may require priming by natural infection or previous vaccination [29,30].",
            "startOffset": 47791,
            "title": "Discussion"
        },
        {
            "endOffset": 27909,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "Other exclusions are listed in Supplementary Table 1.",
            "startOffset": 27856,
            "title": "Subjects"
        },
        {
            "endOffset": 35279,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0065",
            "sentence": "AEs of special interest included new onset of Guillain-Barr\u00e9 syndrome, encephalitis/myelitis (including transverse myelitis), Bell\u2019s palsy, optic neuritis, and brachial neuritis.",
            "startOffset": 35101,
            "title": "Unsolicited AEs"
        },
        {
            "endOffset": 24342,
            "parents": [],
            "refoffsets": {
                "b0030": {
                    "endOffset": 24169,
                    "startOffset": 24166
                }
            },
            "secId": "s0005",
            "sentence": "A high dose, split-virion inactivated trivalent influenza vaccine (IIV3-HD1; Fluzone\u00ae High\u2013Dose, Sanofi Pasteur) [6] has been licensed in adults \u226565 years of age in the United States since 2009, Canada since 2015, Australia since 2017, Brazil since 2018, and the United Kingdom since 2019.",
            "startOffset": 23268,
            "title": "Introduction"
        },
        {
            "endOffset": 31770,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0050",
            "sentence": "After washing, o-phenylenediamine dihydrochloride was added and color detected.",
            "startOffset": 31691,
            "title": "Measurement of neuraminidase antibody titers"
        },
        {
            "endOffset": 32488,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0055",
            "sentence": "Serially diluted, heat-inactivated human serum samples were pre-incubated with a fixed amount of challenge virus and then incubated overnight with Madin-Darby canine kidney cells.",
            "startOffset": 32309,
            "title": "Measurement of seroneutralisation antibody titers"
        },
        {
            "endOffset": 33266,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0060",
            "sentence": "For 7 days after the vaccination, using a diary card, subjects recorded daily temperature, with the route by which it was taken; daily measurement or intensity grade of all other solicited injection site and systemic reactions; and action taken.",
            "startOffset": 33021,
            "title": "Solicited reactions"
        },
        {
            "endOffset": 40704,
            "parents": [
                {
                    "id": "s0080",
                    "title": "Results"
                }
            ],
            "secId": "s0085",
            "sentence": "Mean ages and age distributions were similar, with approximately two-thirds of subjects <75 years of age.",
            "startOffset": 40599,
            "title": "Subjects"
        },
        {
            "endOffset": 46103,
            "parents": [
                {
                    "id": "s0080",
                    "title": "Results"
                }
            ],
            "secId": "s0130",
            "sentence": "The subject had a recent viral infection and was deficient in vitamin B12.",
            "startOffset": 46029,
            "title": "Unsolicited AEs"
        },
        {
            "endOffset": 40598,
            "parents": [
                {
                    "id": "s0080",
                    "title": "Results"
                }
            ],
            "secId": "s0085",
            "sentence": "In all three groups, just over half of the subjects were female, most were White and not Hispanic or Latino.",
            "startOffset": 40490,
            "title": "Subjects"
        },
        {
            "endOffset": 42736,
            "parents": [
                {
                    "id": "s0080",
                    "title": "Results"
                },
                {
                    "id": "s0090",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0105",
            "sentence": "Seroconversion rates were 36.5% (95%CI: 34.2%\u201338.9%) for IIV4-HD, 39.0% (95%CI: 34.3%\u201343.8%) for IIV3-HD1, and 15.2% (95%CI: 11.9%\u201318.9%) for IIV3-HD2.",
            "startOffset": 42585,
            "title": "HAI antibody response to the B Victoria-lineage strain"
        },
        {
            "endOffset": 46428,
            "parents": [],
            "refoffsets": {
                "b0035": {
                    "endOffset": 46427,
                    "startOffset": 46424
                }
            },
            "secId": "s0135",
            "sentence": "The high-dose trivalent inactivated influenza vaccine, IIV3-HD, was licensed in adults \u226565 years of age based on its ability to provide a clinically relevant improvement in protection against laboratory-confirmed influenza and influenza-related medical events over the standard-dose trivalent vaccine, IIV3-SD [7].",
            "startOffset": 46114,
            "title": "Discussion"
        },
        {
            "endOffset": 28515,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "IIV3-HD2 was an alternate formulation of IIV3-HD and contained the WHO/FDA-recommended A/H1N1, A/H3N2, and B Yamagata-lineage strains for the 2017\u20132018 Northern Hemisphere influenza season (batch UD19522).",
            "startOffset": 28310,
            "title": "Vaccines"
        },
        {
            "endOffset": 39960,
            "parents": [
                {
                    "id": "s0080",
                    "title": "Results"
                }
            ],
            "secId": "s0085",
            "sentence": "All subjects were vaccinated as randomized (1777 to IIV4-HD, 443 to IIV3-HD1, and 450 to IIV3-H2) (Fig. 1).",
            "startOffset": 39853,
            "title": "Subjects"
        },
        {
            "endOffset": 34201,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0060",
            "sentence": "All other solicited reactions were scored as grade 1 if transient, requiring minimal therapeutic intervention, or did not interfere with daily activities; grade 2, if they required additional therapeutic intervention or interfered with daily activities but posed no significant permanent risk; and grade 3 if they interrupted usual daily activities, significantly affected clinical status, or required intensive therapeutic intervention.",
            "startOffset": 33764,
            "title": "Solicited reactions"
        },
        {
            "endOffset": 41032,
            "parents": [
                {
                    "id": "s0080",
                    "title": "Results"
                },
                {
                    "id": "s0090",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0095",
            "sentence": "For all four strains, HAI GMTs and seroconversion rates induced by IIV4-HD were non-inferior to those induced by IIV3-HDs containing the same strains (Fig. 2).",
            "startOffset": 40873,
            "title": "Non-inferiority and superiority of HAI GMTs and seroconversion rates"
        },
        {
            "endOffset": 29722,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0040",
            "sentence": "The vaccine administrator was not involved in any of the blinded study assessments (e.g., safety).",
            "startOffset": 29624,
            "title": "Blinding"
        },
        {
            "endOffset": 35834,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0070",
            "sentence": "The per-protocol analysis set was defined as all subjects in the full analysis set who did not have a major protocol deviation.",
            "startOffset": 35707,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 42584,
            "parents": [
                {
                    "id": "s0080",
                    "title": "Results"
                },
                {
                    "id": "s0090",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0105",
            "sentence": "For the B Victoria-lineage strain, the post-vaccination HAI GMT was similar for IIV4-HD (516 [95%CI: 488\u2013545]) and IIV3-HD containing the B Victoria-lineage strain (IIV3-HD1) (476 [95%CI: 426\u2013532]) but lower for IIV3-HD containing the B Yamagata-lineage strain (IIV3-HD2) (253 [95%CI: 226\u2013283]) (Table 4).",
            "startOffset": 42279,
            "title": "HAI antibody response to the B Victoria-lineage strain"
        },
        {
            "endOffset": 45867,
            "parents": [
                {
                    "id": "s0080",
                    "title": "Results"
                }
            ],
            "secId": "s0130",
            "sentence": "An AE of special interest, considered by the investigator as possibly vaccine related, was reported for one subject.",
            "startOffset": 45751,
            "title": "Unsolicited AEs"
        },
        {
            "endOffset": 40353,
            "parents": [
                {
                    "id": "s0080",
                    "title": "Results"
                }
            ],
            "secId": "s0085",
            "sentence": "The primary analysis of non-inferiority was conducted in the 2533 subjects who completed the active study period according to protocol.",
            "startOffset": 40218,
            "title": "Subjects"
        },
        {
            "endOffset": 32308,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0055",
            "sentence": "Seroneutralisation antibody titers were measured as an exploratory endpoint.",
            "startOffset": 32232,
            "title": "Measurement of seroneutralisation antibody titers"
        },
        {
            "endOffset": 50629,
            "parents": [],
            "secId": "s0135",
            "sentence": "Another limitation is that this study did not directly measure protection against influenza infection, although findings from the HAI, seroneutralisation, and anti-neuraminidase antibody measurements consistently indicated that IIV4-HD should provide improved protection over IIIV3-HD against influenza infection.",
            "startOffset": 50316,
            "title": "Discussion"
        },
        {
            "endOffset": 23016,
            "parents": [],
            "refoffsets": {
                "b0005": {
                    "endOffset": 23015,
                    "startOffset": 23012
                }
            },
            "secId": "s0005",
            "sentence": "Adults \u226565 years of age are particularly vulnerable to complications associated with influenza and are at the highest risk for seasonal influenza-related hospitalizations and deaths [1].",
            "startOffset": 22830,
            "title": "Introduction"
        },
        {
            "endOffset": 38085,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0070",
            "sentence": "The secondary objective of superiority was achieved if superiority was demonstrated for both B strains and for both GMTs and seroconversion rates in the full analysis set.",
            "startOffset": 37914,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 51165,
            "parents": [],
            "secId": "s0135",
            "sentence": "In conclusion, the current study demonstrated that, as with IIV4-SD, adding a second B strain in IIV4-HD resulted in improved immunogenicity against the added strain without compromising the immunogenicity of the other strains or the vaccine\u2019s tolerability.",
            "startOffset": 50908,
            "title": "Discussion"
        },
        {
            "endOffset": 42220,
            "parents": [
                {
                    "id": "s0080",
                    "title": "Results"
                },
                {
                    "id": "s0090",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0100",
            "sentence": "For the A/H3N2 strain, seroconversion rates were 49.8% (95%CI: 47.3%\u201352.2%) for IIV4-HD and 50.5% (95%CI: 47.1%\u201353.9%) for the pooled IIV3-HDs.",
            "startOffset": 42077,
            "title": "HAI antibody response to influenza A strains"
        },
        {
            "endOffset": 30681,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0045",
            "sentence": "If the lowest/first serum dilution used in the assay (1:10) did not result in complete inhibition of hemagglutination, the serum HAI titer was reported as <10.",
            "startOffset": 30522,
            "title": "Measurement of HAI antibody titers"
        },
        {
            "endOffset": 35380,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0065",
            "sentence": "For all AEs and SAEs, investigators recorded duration and the potential relationship to vaccination.",
            "startOffset": 35280,
            "title": "Unsolicited AEs"
        },
        {
            "endOffset": 24790,
            "parents": [],
            "refoffsets": {
                "b0035": {
                    "endOffset": 24789,
                    "startOffset": 24786
                }
            },
            "secId": "s0005",
            "sentence": "In a phase III multicenter efficacy study including 31,989 adults \u226565 years of age in the US and Canada, IIV3-HD was 24.2% more effective in preventing laboratory-confirmed influenza caused by any strain relative to a standard-dose trivalent split-virion inactivated influenza vaccine (IIV3-SD) [7].",
            "startOffset": 24491,
            "title": "Introduction"
        },
        {
            "endOffset": 23105,
            "parents": [],
            "refoffsets": {
                "b0010": {
                    "endOffset": 23104,
                    "startOffset": 23099
                },
                "b0015": {
                    "endOffset": 23104,
                    "startOffset": 23099
                }
            },
            "secId": "s0005",
            "sentence": "This appears to be due to decreasing immune responses and increased comorbidities [2,3].",
            "startOffset": 23017,
            "title": "Introduction"
        },
        {
            "endOffset": 49000,
            "parents": [],
            "secId": "s0135",
            "sentence": "This study demonstrated that, despite the increase in total antigen dose, IIV4-HD was well tolerated and had a similar safety profile as IIV3-HD.",
            "startOffset": 48855,
            "title": "Discussion"
        },
        {
            "endOffset": 48702,
            "parents": [],
            "secId": "s0135",
            "sentence": "Despite the higher dose of antigen in IIV4-HD, previous exposure to influenza vaccine reduced antibody titers and seroconversion rates.",
            "startOffset": 48567,
            "title": "Discussion"
        },
        {
            "endOffset": 35549,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0070",
            "sentence": "The primary endpoints, HAI antibody titer and seroconversion rate, were analyzed in both the per-protocol analysis set and the full analysis set.",
            "startOffset": 35404,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 30002,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "refoffsets": {
                "b0100": {
                    "endOffset": 30001,
                    "startOffset": 29997
                }
            },
            "secId": "s0045",
            "sentence": "HAI titers were detected as described previously [20].",
            "startOffset": 29948,
            "title": "Measurement of HAI antibody titers"
        },
        {
            "endOffset": 37395,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0070",
            "sentence": "The primary immunogenicity objective was achieved if non-inferiority was demonstrated for all four strains and for both GMTs and seroconversion rates in the per-protocol analysis set.",
            "startOffset": 37212,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 28597,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "All vaccines were administered by intramuscular injection as sterile suspensions.",
            "startOffset": 28516,
            "title": "Vaccines"
        },
        {
            "endOffset": 38315,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0070",
            "sentence": "Only descriptive analyses were performed for safety endpoints.",
            "startOffset": 38253,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 40413,
            "parents": [
                {
                    "id": "s0080",
                    "title": "Results"
                }
            ],
            "secId": "s0085",
            "sentence": "Safety follow-up to month 6 was completed by 2642 subjects.",
            "startOffset": 40354,
            "title": "Subjects"
        },
        {
            "endOffset": 45427,
            "parents": [
                {
                    "id": "s0080",
                    "title": "Results"
                }
            ],
            "secId": "s0125",
            "sentence": "For each solicited reaction, fewer than 1% of subjects reported it as grade 3.",
            "startOffset": 45349,
            "title": "Solicited reactions"
        },
        {
            "endOffset": 44710,
            "parents": [
                {
                    "id": "s0080",
                    "title": "Results"
                },
                {
                    "id": "s0090",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0120",
            "sentence": "For the two B-lineage strains, post-vaccination seroneutralisation GMTs and geometric mean post-/pre-vaccination titer ratios (GMTRs) were similar for IIV4-HD and IIV3-HD when it contained the same B-lineage strain but higher for IIV4-HD when it contained the B-lineage strain not included in the IIV3-HD.",
            "startOffset": 44405,
            "title": "Seroneutralisation and anti-neuraminidase antibody responses"
        },
        {
            "endOffset": 38252,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0070",
            "sentence": "Solicited reactions and AEs were analyzed in the safety analysis set, defined as all subjects who received a study vaccine; analyzed according to the vaccine received.",
            "startOffset": 38085,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 48194,
            "parents": [],
            "secId": "s0135",
            "sentence": "In this study, the HAI GMT for strain A/H1N1 was slightly lower for IIV4-HD than for the pooled IIV3-HDs.",
            "startOffset": 48089,
            "title": "Discussion"
        },
        {
            "endOffset": 41199,
            "parents": [
                {
                    "id": "s0080",
                    "title": "Results"
                },
                {
                    "id": "s0090",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0095",
            "sentence": "For both B strains, HAI GMTs and seroconversion rates induced by IIV4-HD were superior to those induced by IIV3-HD not containing the same B-strain lineage (Table 3).",
            "startOffset": 41033,
            "title": "Non-inferiority and superiority of HAI GMTs and seroconversion rates"
        },
        {
            "endOffset": 30214,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0045",
            "sentence": "Briefly, test and control sera were incubated with Type III neuraminidase to eliminate non-specific inhibitors and then with a suspension of Turkey red blood cells to adsorb spontaneous anti-species agglutinins.",
            "startOffset": 30003,
            "title": "Measurement of HAI antibody titers"
        },
        {
            "endOffset": 32852,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0055",
            "sentence": "The neutralization titer (1/dilution) was calculated from the intersection of the optical density curve of the test sample and the 50% neutralization point of the control optical density curve.",
            "startOffset": 32659,
            "title": "Measurement of seroneutralisation antibody titers"
        },
        {
            "endOffset": 49587,
            "parents": [],
            "secId": "s0135",
            "sentence": "Post-licensure monitoring will be conducted to confirm the safety of IIV4-HD.",
            "startOffset": 49510,
            "title": "Discussion"
        },
        {
            "endOffset": 50315,
            "parents": [],
            "secId": "s0135",
            "sentence": "Further investigation is warranted to determine whether these results will be generalizable to frail or institutionalized older adults.",
            "startOffset": 50180,
            "title": "Discussion"
        },
        {
            "endOffset": 49858,
            "parents": [],
            "refoffsets": {
                "b0175": {
                    "endOffset": 49857,
                    "startOffset": 49853
                }
            },
            "secId": "s0135",
            "sentence": "Small-fiber neuropathy has been reported following vaccination for other diseases [35].",
            "startOffset": 49771,
            "title": "Discussion"
        },
        {
            "endOffset": 41484,
            "parents": [
                {
                    "id": "s0080",
                    "title": "Results"
                },
                {
                    "id": "s0090",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0095",
            "sentence": "These results were confirmed by repeating the analysis in the alternative analysis set (full analysis set for non-inferiority, per-protocol analysis set for superiority) and by analysis of covariance using post-vaccination HAI titers adjusted for baseline HAI titers (data not shown).",
            "startOffset": 41200,
            "title": "Non-inferiority and superiority of HAI GMTs and seroconversion rates"
        },
        {
            "endOffset": 41933,
            "parents": [
                {
                    "id": "s0080",
                    "title": "Results"
                },
                {
                    "id": "s0090",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0100",
            "sentence": "Post-vaccination HAI GMTs were similar between IIV4-HD and the pooled IIV3-HDs for strains A/H1N1 (312 [95%CI: 292\u2013332] for IIV4-HD vs. 374 [95%CI: 341\u2013411] for IIV3-HD) and A/H3N2 (563 [95%CI: 525\u2013603] for IIV4-HD vs. 594 [95%CI: 540\u2013653] for IIV3-HD) (Table 4).",
            "startOffset": 41670,
            "title": "HAI antibody response to influenza A strains"
        },
        {
            "endOffset": 34615,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0065",
            "sentence": "Unsolicited AEs were collected up to the end of the active phase of the study (day 28\u201335).",
            "startOffset": 34525,
            "title": "Unsolicited AEs"
        },
        {
            "endOffset": 30841,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0045",
            "sentence": "If the highest/last serum dilution used in the assay (1:10,240) exhibited complete inhibition of hemagglutination, the serum HAI titer was reported as \u226510,240.",
            "startOffset": 30682,
            "title": "Measurement of HAI antibody titers"
        },
        {
            "endOffset": 34524,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "refoffsets": {
                "b0115": {
                    "endOffset": 34451,
                    "startOffset": 34447
                },
                "b0120": {
                    "endOffset": 34523,
                    "startOffset": 34519
                }
            },
            "secId": "s0065",
            "sentence": "Unsolicited AEs and serious adverse events (SAEs) were defined as described in the International Conference for Harmonisation E2A Guideline for Clinical Safety Data Management: Definitions and Standards for Expedited Reporting [23] and encoded using the Medical Dictionary for Regulatory Activities [24].",
            "startOffset": 34220,
            "title": "Unsolicited AEs"
        },
        {
            "endOffset": 25521,
            "parents": [],
            "refoffsets": {
                "b0050": {
                    "endOffset": 25520,
                    "startOffset": 25513
                },
                "b0055": {
                    "endOffset": 25520,
                    "startOffset": 25513
                },
                "b0060": {
                    "endOffset": 25520,
                    "startOffset": 25513
                },
                "b0065": {
                    "endOffset": 25520,
                    "startOffset": 25513
                },
                "b0070": {
                    "endOffset": 25520,
                    "startOffset": 25513
                },
                "b0075": {
                    "endOffset": 25520,
                    "startOffset": 25513
                }
            },
            "secId": "s0005",
            "sentence": "Other post-licensure studies have demonstrated a benefit of IIV3-HD over IIV3-SD for the prevention of pneumonia and other cardio-respiratory events, post-influenza death, and healthcare utilization (e.g., hospitalization) in this age group [10\u201315].",
            "startOffset": 25272,
            "title": "Introduction"
        }
    ],
    "docId": "S0264410X19310667",
    "metadata": {
        "asjc": [
            "1313",
            "2400",
            "2725",
            "2739",
            "3400"
        ],
        "authors": [
            {
                "email": "Lee-Jah.Chang@sanofi.com",
                "first": "Lee Jah",
                "initial": "L.J.",
                "last": "Chang"
            },
            {
                "email": null,
                "first": "Ya",
                "initial": "Y.",
                "last": "Meng"
            },
            {
                "email": null,
                "first": "Helene",
                "initial": "H.",
                "last": "Janosczyk"
            },
            {
                "email": null,
                "first": "Victoria",
                "initial": "V.",
                "last": "Landolfi"
            },
            {
                "email": null,
                "first": "H. Keipp",
                "initial": "H.K.",
                "last": "Talbot"
            },
            {
                "email": null,
                "first": null,
                "initial": null,
                "last": null
            }
        ],
        "doi": "10.1016/j.vaccine.2019.08.016",
        "firstpage": "5825",
        "issn": "0264410X",
        "keywords": [
            "Clinical trial",
            "Elderly adults",
            "High-dose influenza vaccine",
            "Immunogenicity",
            "Quadrivalent influenza vaccine",
            "Safety"
        ],
        "lastpage": "5834",
        "openaccess": "Full",
        "pub_year": 2019,
        "subjareas": [
            "BIOC",
            "IMMU",
            "MEDI",
            "VETE"
        ],
        "title": "Safety and immunogenicity of high-dose quadrivalent influenza vaccine in adults \u226565\u202fyears of age: A phase 3 randomized clinical trial"
    }
}